NEW YORK, NY / ACCESSWIRE / May 28, 2020 / Hardships during our childhood years often have a long and profound impact on our lives. Alex Saenz experienced a childhood full of difficulties and hardship that he was able to overcome and become the person he is today. Instead of letting it get him down, he used it as fuel to achieve his dreams.

"I grew up in West Phoenix from very humble beginnings. I lived in a trailer park from the age of 13-18. During the ages of 13-18, my parents divorced and I dealt with a lot of emotional and mental issues such as anxiety, depression, loneliness and abandonment. Having felt all this, I worked my butt off in high school and graduated with a 4.2 GPA." recounts Alex.

With this kind of GPA, Alex had the opportunity to go to plenty of elite colleges. Instead, his interest was piqued by real estate investing. Though he had very little money in his bank account, Alex wanted to achieve his goal of making six or seven figures, so he began his venture into real estate.

"At the time of jumping into real estate, I had less than $500 in his bank account. This was money I had saved up from working at a grocery store pushing carts where I only made $7.50 an hour from pushing carts. Having no emotional or financial support, I dove into real estate head first by door knocking and putting signs out on street corners. It took me nine months to get my first real estate wholesale deal. During this time, my mom moved to Nevada, which was 18 hours away. I then had to move into my friend's house and work out of my friend's little brother's room, which was Spiderman themed. I started to dig deeper and work harder by marketing for real estate deals." States Alex.

Though these months were difficult for Alex, like before, he pushed through it and finally made his first closing. This first deal changed everything for Alex. He was only 19 and had already closed a sale and quickly began closing other sales. He began to expand his team and hire other agents to help build his business and close more sales.

"Having closed my first real estate deal by January 2016, I took off in real estate. I was 19 when I closed my first real estate deal! In 2016, still at the age of 19, I closed 12 real estate wholesale deals for $120,000 in revenue. Keeping living expenses low, I invested nearly everything back into business. I hired two sales guys to help hunt down more real estate deals, by 2017, the real estate company grew to five total team members!" exclaims Alex.

Alex has never looked back since beginning his journey. His business took off and he was able to create his real estate business All in Entrepreneurs with his two partners: Carlos Reyes and Sal Shakir. He also has started creating youtube videos in which he shares his life story and ways to help others learn the tricks of the real estate trade.

"In 2017, my company closed 62 deals for $615,000 in revenue with more than 60% profit margins. This was all done at 20 years young. In 2018, being 21, I continued to grow my real estate company and Co-Founded ALL IN ENTREPRENEURS with his partners Carlos Reyes and Sal Shakir. In 2018, Over 100 deals were closed, and it was the first 7 figure year in business and I was only 21. Fast forward to 2020, I have closed over 300+ deals with my 7 figure real estate acquisition firm." states Alex.

Though Alex has faced numerous challenges, he has worked hard to overcome them and achieve his goals. He has always had a good mindset, which has helped him come as far as he has at such a young age. In the future, Alex hopes to keep expanding his real estate business as well as continue pioneering his new solar power company.

"I am a millionaire now, currently 23 years old, building more companies, earning 6 figures monthly through real estate, and consulting solar and SAS (tech/software) companies. I am most excited to help others overcome poverty, bad programming and helping younger entrepreneurs achieve success at a young age!" Remarks Alex.

If you want to learn more about Alex's amazing life story, you can check out his YouTube channel by subscribing to Alex Saenz on YouTube. In addition, you can follow him on Instagram @alexsaenz and check out his business at allinnation.com

CONTACT:

Paula Henderson
202-539-7664
phendersonnews@gmail.com

About VIP Media Group

VIP Media Group is a hybrid PR agency. Their diverse client base includes top-class entrepreneurs, public figures, influencers, and celebrities.

SOURCE: VIP-Media

ReleaseID: 591852

VANCOUVER, BC / ACCESSWIRE / May 28, 2020 / NHS Industries Ltd. (CSE:NHS) (the "Company" or "NHS") has provided an update on the filing of its annual financial statements and related disclosures for the year ended Dec. 31, 2019, following the earlier announcement in its press release dated April 16, 2020, that filing of the annual disclosures would be delayed due to COVID-19-related delays. The company is continuing to work diligently and expeditiously with its auditors, and anticipates that the annual disclosures will be filed by June 12, 2020, as previously indicated.

The company further announces that filing of the interim financial statements and related disclosures for the three-month period ended March 31, 2020, the first quarter of fiscal 2020, will also be delayed owing to COVID-19-related issues. The company anticipates that the interim disclosures will be filed by July 13, 2020.

NHS confirms that there have been no material business developments other than as disclosed in its press releases and previous filings, and further confirms that management and other insiders of the company have been, since April 16, 2020, and continue to be, subject to a trading blackout policy that reflects the principles in Section 9 of National Policy 11-207 — Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions, which will remain in effect until both the annual disclosures and the interim disclosures have been filed.

About NHS Industries Ltd.

NHS is an agri-food holdings company focused on innovative products and technologies in the food services industry.

For further information about NHS, please consult the Company's profile on SEDAR at www.sedar.com.

On Behalf of the Board of Directors

Robert Nygren
Chief Executive Officer
info@nhsindustries.ca
(888) 202-5153

WWW.NHSINDUSTRIES.CA

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to completion of planned improvements on schedule and on budget, the availability of financing needed to complete the Company's planned improvements on commercially reasonable terms, delays in obtaining statutory and/or regulatory approval for production plans, the ability to mitigate the risk of loss through appropriate insurance policies, among others. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

SOURCE: NHS Industries Ltd.

ReleaseID: 591854

BOSTON, MA / ACCESSWIRE / May 28, 2020 / Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that a securities fraud lawsuit has been filed against Hamilton Beach Brands Holding Company (NYSE:HBB) and certain of its officers. Investors who have lost money are encouraged to contact the firm for a free case evaluation.

On May 11, 2020, Hamilton Beach Brands disclosed that it could not timely file its first-quarter 2020 quarterly financial report due to "certain accounting irregularities with respect to the timing of recognition of selling and marketing expenses and the classification of certain expenditures within the statement of operations at its Mexican subsidiary." In addition, the Company stated that its "Audit Review Committee has commenced an internal investigation, with the assistance of outside counsel and other third-party experts," concerning "the realizability of certain assets of the Mexican subsidiary."

On this news, shares of Hamilton Beach Brands common stock fell by approximately 9%, or $1.03 per share, to close at just $10.43 per share on unusually heavy trading volume.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm's lawyers have recovered billions of dollars for its clients. Please contact us at (617) 398-5600, via email at cases@blockesq.com, or at https://shareholder.law/hbb.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockesq.com
www.blockesq.com

SOURCE: Block & Leviton LLP

ReleaseID: 591847

VANCOUVER, BC and BOSTON, MA / ACCESSWIRE / May 28, 2020 / Imagin Medical (CSE:IME) (OTCQB:IMEXF) (Frankfurt & Stuttgart Symbol:DPD2) ("Imagin" or the "Company") today reported financial results for the three months ended March 31, 2020. All amounts, unless otherwise specified, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards (IFRS).

Recent Corporate Developments

On January 20, 2020, Imagin closed an oversubscribed non-brokered private placement for gross proceeds of $1,914,000.
On February 17, 2020, the Company presented at the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference.
On March 10, 2020, Imagin reported ongoing market research feedback on its i/BlueTM Imaging System, which focused on the i/Blue's ability to display side-by-side white and blue light images simultaneously, which would enable real-time cancer visualization during resection.
On May 12, 2020, the Company announced its support of Bladder Cancer Awareness Month.
On May 14, 2020, Imagin reported on its response to COVID-19, including expense reductions and cost structure improvements to extend Imagin's cash runway.
On May 21, 2020, the Company announced that it had received functional i/Blue Imaging Systems from Optel, Inc., its contract design and development firm, which will be used to conduct in vivo studies and virtual demonstrations for evaluation by leading urologists.

"During the quarter, we focused on adapting our business to align with the conditions caused by the COVID-19 pandemic and put several initiatives in place to extend our cash runway," said Jim Hutchens, Imagin's President and CEO. "Our focus remains on advancing the i/Blue Imaging System toward commercialization, and we are looking forward to using our new functional units to demonstrate the system's features and performance via virtual meetings with investors, urologists and key opinion leaders. While we await resumption of normal clinical device study activities – which would allow us to proceed with our planned first-in-human studies of i/Blue – we will continue to explore alternative in vivo study options."

Summary Fiscal 2020 Second Quarter Financial Results

Total operating expenses for the second quarter of fiscal 2020 were $1,837,890, compared with $970,745 for the same quarter in 2019, and consisted primarily of research and development ("R&D") and general and administrative ("G&A") expenses. R&D expenses for the second quarter of fiscal 2020 were $1,207,381 compared with $439,404 in the same quarter in 2019. The increase in R&D was primarily attributable to the work performed by outsourced design and engineering, regulatory, U.S. Food and Drug Administration ("FDA"), legal and quality consultants for the design and development of the i/Blue System and associated FDA and regulatory plans. G&A expenses for the second quarter of fiscal 2020 were $351,767, compared with $420,505 for the same quarter in 2019. The decrease in G&A expenses was primarily attributable to a $29,857 and $50,457 decrease in business development and consulting, fees; partially offset by a $7,519 and $4,057 increase in legal & accounting and management fees, respectively.

Net loss for the three months ended March 31, 2020 was $1,870,290, or $0.01 loss per common share, compared to a net loss of $926,070, or $0.01 loss per common share for the three months ended March 31, 2019.

Liquidity and Outstanding Share Capital

As at March 31, 2020, the Company had cash of $904,174.

As at May 28, 2020, Imagin had an unlimited number of authorized common shares with 177,340,278 common shares issued and outstanding.

The Company's financial statements and management's discussion and analysis are available on www.sedar.com.

Conference Call Details

Imagin is pleased to invite all interested parties to participate in a conference call today, May 28, 2020, at 5:00 p.m. ET during which the results will be discussed.

Live Call: 844-369-8770 (Canada and the United States)
862-298-0840 (International)

Replay: 919-882-2331(Canada and the United States)
Replay ID: 35004

The call will also be broadcast live and archived on the Company's website at www.imaginmedical.com under "Events & Presentations."

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The Company's initial focus is bladder cancer. Learn more at www.imaginmedical.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company's imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Contacts:

Stephen Kilmer, Investor Relations
Telephone: 647-872-4849
Email: stephen@kilmerlucas.com

Jim Hutchens, President & CEO
Telephone: 833-246-2446

SOURCE: Imagin Medical

ReleaseID: 591836

NEW YORK, NY / ACCESSWIRE / May 28, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

EHTH Shareholders Click Here: https://www.zlk.com/pslra-1/ehealth-inc-loss-form?prid=6980&wire=1
FITB Shareholders Click Here: https://www.zlk.com/pslra-1/fifth-third-bancorp-loss-form?prid=6980&wire=1
CTMX Shareholders Click Here: https://www.zlk.com/pslra-1/cytomx-therapeutics-inc-loss-submission-form?prid=6980&wire=1

* ADDITIONAL INFORMATION BELOW *

eHealth, Inc. (NASDAQ:EHTH)

EHTH Lawsuit on behalf of: investors who purchased March 19, 2018 – April 7, 2020
Lead Plaintiff Deadline: June 8, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ehealth-inc-loss-form?prid=6980&wire=1

The complaint alleges that eHealth, Inc. issued materially false and/or misleading information and/or failed to disclose: (1) its highly aggressive accounting and modeling assumptions; (2) its skyrocketing rate of member churn, resulting from eHealth's pursuit of low quality, lossmaking growth; (3) its reliance on direct response television advertising, which attracts an unprofitable, high churn enrollee; and (4) that as a result of the foregoing, defendants' public statements were materially false and misleading at all relevant times.

Fifth Third Bancorp (NASDAQ:FITB)

FITB Lawsuit on behalf of: investors who purchased February 26, 2016 – March 6, 2020
Lead Plaintiff Deadline: June 8, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fifth-third-bancorp-loss-form?prid=6980&wire=1

According to the filed complaint, during the class period, Fifth Third Bancorp made materially false and/or misleading statements and/or failed to disclose that: (i) as a result of Fifth Third Bank's aggressive incentive policies to promote its cross-sell strategy, Fifth Third Bank employees engaged in unauthorized conduct with customer accounts; (ii) since at least 2008, Fifth Third Bank, and by extension, Fifth Third, was aware of such unauthorized conduct and, thus, that it was violating relevant regulations and laws aimed at protecting its consumers; (iii) Fifth Third failed to properly implement and monitor its cross-sell program, detect and stop misconduct, and identify and remediate harmed consumers; (iv) all the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny or investigation; (v) Fifth Third's revenues were in part the product of unlawful conduct and thus unsustainable; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

CytomX Therapeutics, Inc. (NASDAQ:CTMX)

CTMX Lawsuit on behalf of: investors who purchased May 17, 2018 – May 13, 2020
Lead Plaintiff Deadline: July 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cytomx-therapeutics-inc-loss-submission-form?prid=6980&wire=1

According to the filed complaint, during the class period, CytomX Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
http://www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 591846

BALTIMORE, MD / ACCESSWIRE / May 28, 2020 / Paice and Daimler have reached an agreement to license patented hybrid technology.

Paice was an early leader in electrified vehicles. The company was awarded its first hybrid vehicle patent in 1994, long before most automakers began seriously focusing on ways to improve fuel efficiency and reduce emissions. Paice's technology proved valuable and helped accelerate the growth of the hybrid vehicle industry. An independent analysis concluded that Paice owns the most dominant hybrid vehicle patents in the world.

"We've reached several licensing agreements in the past two years without the need for litigation. These agreements make a lasting impact in our community by supporting the good works of the Abell Foundation," said Paice Executive Chairman Frances Keenan.

During the company's early years, Severinsky worked closely with two experienced automotive veterans: Bob Templin, a Paice board member who had served as chief engineer of Cadillac and technical director of GM's Research Laboratory; and Ted Louckes, a 40-year veteran of General Motors who served as Paice's Chief Operating Officer and was instrumental in developing Paice's hybrid technology alongside Dr. Severinsky.

About Paice (www.paicehybrid.com)

Dr. Alex Severinsky, a Russian immigrant, founded Paice in 1992 with the support of the University of Maryland. The company has been awarded 30 U.S. and foreign patents. It has licensing agreements with many of the world's leading automakers.

About the Abell Foundation (www.abell.org)

The Abell Foundation, a Baltimore-based charitable organization dedicated to fighting urban poverty and promoting social objectives by investing in progressive local start-ups, is a co-owner of the Paice patents. Since 1999, Abell has helped support Paice's efforts to develop and promote its hybrid technology.

For More Information

Joyce Fitzpatrick | joyce@fitzpatrickcomm.com | (919) 247-4400

SOURCE: Paice

ReleaseID: 591838

NEW YORK, NY / ACCESSWIRE / May 29, 2020 / This newspaper's correspondent in Beijing reported on May 28 that the National People's Congress and the Chinese People's Political Consultative Conference were held in Beijing on May 22. In the context of the global epidemic situation, this year's NPC and CPPCC have drawn particular attention from the outside world.

For the United States, the biggest concern is a legislative bill called Hong Kong national security laws: the Decision of the National People's Congress on Establishing and Improving the Legal System and Enforcement Mechanisms for the Hong Kong Special Administrative Region to Safeguard National Security, because it will be related to the U.S. policy towards China and the interests of U.S.-funded U.S. enterprises in China.

It is reported that this bill is not based on Hong Kong's "self-legislating" under Article 23 of Hong Kong's Basic Law, but is a bill empowered by the Constitution and the Basic Law and directly implemented by the National People's Congress on Hong Kong national security issues. The draft bill was submitted to the National People's Congress for deliberation and passed today (May 28).

According to the contents of the previously published bill, the bill will authorize the NPC Standing Committee to enact laws to prevent, stop and punish any act that seriously endangers national security, such as splitting the country, subverting the state power and organizing and implementing terrorist activities, as well as activities of foreign and overseas forces interfering in the affairs of the Hong Kong Special Administrative Region.

The bill has aroused great controversy since its promulgation, but objectively, the enactment of the national security laws is a normal thing for a sovereign country. As a matter of fact, many Hong Kong politicians and businessmen believe that the national security legislation for Hong Kong is too late.

Leung Chun-ying, Hong Kong's former chief executive and now Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference, pointed out that it has been 23 years since Hong Kong's return to the motherland. Due to various obstacles from the opposition, similar laws cannot be passed in Hong Kong, thus failing to meet the needs of national security. Under such circumstances, it is completely reasonable and legal for the NPC to plug the loopholes, and at the same time the NPC absolutely has the power to do so.

Leung said that in the past few years, the opposition has continuously attacked the bottom line of the Chinese Central Government, endangering the national security and causing negative effects in Hong Kong. "But almost every country and every society in the world, including the United States itself, as well as some Asian countries, such as Singapore, have laws in this regard", he said.

Take the United States as an example, there are dozens of existing laws related to national security, including the National Security Act of 1947, the Sedition Act, the Espionage Act, the Alien Enemies Act, the Protect America Act, the Homeland Security Act, the USA PATRIOT Act, etc. These laws are aimed at safeguarding national sovereignty, integrity, security and stability.

It should be pointed out that Hong Kong national security laws are against four kinds of acts, namely splitting of the country, subversion of the Chinese Central Government, intervention by external forces and terrorism. It is not related to the lawful assemblies, processions, lectures and religious activities of ordinary Hong Kong citizens, nor will it affect normal social and economic activities.

Therefore, Hong Kong national security laws are essentially a normal means for China to safeguard its own national interests, rather than a strategy of war with the United States. In the context of the global pandemic of the COVID-19, the United States is facing the severe challenges of the spread of the pandemic and the economic recession. Therefore, for the benefit of the American people, it is more important to focus on seeking international cooperation to combat the epidemic, instead of concentrating on matters that do not involve the core national interests of the United States. In fact, due to the huge amount of US investment in Hong Kong and its many benefits in Hong Kong, the legislation is conducive to Hong Kong's social and economic recovery and is of great benefit to US enterprises in Hong Kong.

Wong Yuk-Shan, deputy head of the Hong Kong National People's Congress delegation, said that since June last year, many violent incidents have affected the people's livelihood in Hong Kong, and the riots have continued for so long without any sign of stopping, causing great losses to the society.

Leung also pointed out that the Hong Kong version national security laws would not hinder foreign investors from investing in Hong Kong, nor would it hinder the freedom enjoyed by local residents according to law; in contrast, the existing national security loopholes in Hong Kong will affect Hong Kong's social stability, thus affecting Hong Kong's economic development.

Certainly, legislation is only the first step, and the key lies in the detailed rules and strength of law enforcement, which is also something we need to pay attention to for a long time. In summary, the United States should not be too sensitive or nervous about Hong Kong national security laws, but should seek win-win cooperation with China within the existing framework.

Global News Online
Cathy Concord
+1 (321) 800-3487
info@globalnewsonline.info

SOURCE: Global News Online

ReleaseID: 591929

Former Metro Executive Brings Experience to CBD Company

LONDON, UK / ACCESSWIRE / May 28, 2020 / Axel Hluchy (55), co-founder and -investor of Reakiro Europe was appointed Managing Partner of the company. He will be responsible for the establishment of the Reakiro brand in the European retail, leisure, wellness and sports sector.

Hluchy is a German graduated economist and holds a degree in Business Administration of the University of Paderborn and a Diploma in European Business of Nottingham Business School. After 5 years with the automotive Group Daimler Benz AG he joined METRO Group in 1997 where he held several executive positions until 2016 of which he served the last 14 years as CEO in Ukraine, Czech Republic, Slovakia and Germany.

"With Axel Hluchy an internationally experienced and highly successful senior retail executive is now contributing his expertise to our activities at Reakiro. He has an excellent network within the European retail sector which will help to position our brand in the European market" said Stuart McKenzie, CEO of Reakiro. "I am so pleased Axel will join our management team as he has an outstanding track record and breadth of business experience, we believe are critical in our next phase of growth and market leadership in the European CBD business."

About Reakiro

Reakiro is a leading EU manufacturer and supplier of premium CBD products and one of the few European manufacturers who can consistently trace the entire product lifecycle from seed to sale. The company offers a full line of CBD and hemp-oil products including skin care creams, capsules, sprays and their signature oils.

Reakiro CBD oil is a full spectrum oil produced from the highest quality of industrial hemp cultivated in the EU and tested by independent third-party laboratories.

Media contact information:
Name: Elena McKenzie
Company: Reakiro
Email: info@reakiro.com
Website: https://cbdreakiro.com/

SOURCE: Reakiro

ReleaseID: 591837

LONDON, UK / ACCESSWIRE / May 28, 2020 / Condor Gold (AIM:CNR)(TSX:COG) is pleased to announce a placing of 18,082,192 Units (as defined below) at a price of 36.5p per Unit (the "Placing Price"), including a Directors & CFO subscription of 2,361,917 Units ("Directors & CFO Subscription"), to raise in aggregate gross proceeds of £6,600,000 (the "Placing") before expenses. The Placing has been undertaken by the Company with institutional and other investors and was over subscribed. Completion of the Placing is conditional, inter alia, upon admission of the Placing Shares to trading on AIM. The Company has received conditional approval from the Toronto Stock Exchange (the "TSX") for the Placing. The Placing Price represents a discount of 17.6% to the volume-weighted-average price over the 20 trading days prior to 28 May 2020.

Each Unit comprises one ordinary share of 20p each in the Company (a "Placing Share") and one half of one share purchase warrant of the Company (a "Warrant"). Each Warrant, which is unlisted and fully transferable, will entitle the holder thereof to purchase one ordinary share at a price of 40p (which is an approximate 10% premium to the Placing Price) for a period of 36 months from the date on which the shares are issued pursuant to the Placing. 50% of the Warrants shall be subject to an accelerated exercise period if the closing mid-market price of the ordinary shares on AIM is more than 55p for 10 consecutive trading days. All of the securities comprising the Units are subject to resale restrictions into Canada which will expire four months and one day from the date of Admission of the Placing Shares to AIM.

Mark Child, Chairman and Chief Executive Officer of Condor, commented:

"Condor Gold has conducted a private placement, issuing new ordinary shares representing 19% of the Company's existing issued share capital, to raise gross proceeds of £6,600,000. The placement proceeds will be used to advance the La India Project towards production. Condor has a high grade 1.12 million oz gold open pit Mineral Resource, including Mineral Reserves permitted for extraction from 3 open pits. A processing plant and associated mine site infrastructure is also permitted. The placement proceeds will be used to complete engineering and other technical studies, purchase land in and around the minesite infrastructure and place a deposit on a processing plant. Condor's intention is to permit the 1.2 million oz gold underground Mineral Resource following the commencement of open pit production and continue with exploration activity to demonstrate a 5 million oz Gold District at La India Project."

Details of the Placing and proposed Directors & CFO Subscription

A total of 18,082,192 Units (comprised of 18,082,192 Placing Shares and 9,041,090 Warrants) have been placed with placees at the Placing Price to raise gross proceeds of £6,600,000. Total fees or commissions payable to agents amount to £193,885. The net amount raised by the Company through the Placement totals £6,406,115.

As part of the Placing, the Company advises that through the Directors & CFO Subscription, four Directors of the Company, namely Mark Child, Andrew Cheatle, Ian Stalker and Jim Mellon, along with Jeffrey Karoly (Chief Financial Officer), have subscribed for 27,397, 10,000, 67,370 2,247,150 and 10,000 Units respectively, for a total of 2,361,917 Units (comprising 2,361,917 shares and 1,180,958 share purchase warrants of the Company).

Jim Mellon has subscribed (the "Mellon Subscription"), through Galloway Limited, a limited company which is wholly owned by Burnbrae Group Limited, which is in turn wholly owned by Jim Mellon, for a total of 2,247,150 Units (comprising 2,247,150 Placing Shares (the "Mellon Shares") and 1,123,575 share purchase warrants of the Company) on the same terms for a sum of £820,210. Following completion of the Mellon Subscription, Jim Mellon shall own a direct and indirect aggregate shareholding of 16,985,297 Ordinary Shares or 15.0% of the Company. His direct interest will be in 2,889,883 Ordinary Shares and the indirect interest will be in 14,095,414 Ordinary Shares held through Galloway Limited.

Andrew Cheatle has subscribed (the "Cheatle Subscription") for a total of 10,000 Units (comprising 10,000 Placing Shares and 5,000 share purchase warrants of the Company). Following completion of the Cheatle Subscription, Andrew Cheatle shall own directly and indirectly a shareholding of 99,884 Ordinary shares of the Company, representing 0.1% of the resultant issued share capital.

Ian Stalker has subscribed (the "Stalker Subscription") through Promaco Limited, a limited company which is wholly owned by a trust for the Stalker family, for a total of 67,370 Units (comprising 67,370 Placing Shares and 33,685 share purchase warrants of the Company). Following completion of the Stalker Subscription, Ian Stalker shall have a direct or indirect interest in 67,370 Ordinary shares of the Company, representing 0.1% of the resultant issued share capital.

Mark Child has subscribed (the "Child Subscription") for a total of 27,397 Units (comprising 27,397 Placing Shares and 13,698 share purchase warrants of the Company). Following completion of the Child Subscription, Mark Child shall directly and indirectly a shareholding of 4,171,564 Ordinary shares of the Company, representing 3.7% of the resultant issued share capital.

Jeffrey Karoly has subscribed (the "Karoly Subscription") for a total of 10,000 Units (comprising 10,000 Placing Shares and 5,000 share purchase warrants of the Company). Following completion of the Karoly Subscription, Jeffrey Karoly shall own directly and indirectly a shareholding of 122,412 Ordinary shares of the Company, representing 0.1% of the resultant issued share capital.

Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission"), with Admission of the Placing Shares expected to occur on or around 2 June 2020.

The Placing Shares will rank pari passu with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared after the date of their issue.

Following Admission of the Placing Shares, the Company will have 113,245,714 ordinary shares of 20p each in issue with voting rights and admitted to trading on AIM and this figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Related Party Transaction

The subscription by each of Jim Mellon (through Galloway Limited), Mark Child, Ian Stalker and Andrew Cheatle ("Directors Subscriptions") is a Related Party Transaction under Rule 13 of the AIM Rules for Companies by virtue of Jim Mellon, Andrew Cheatle, Ian Stalker and Mark Child being Directors of the Company. Accordingly, the Independent Director, being Kate Harcourt, confirms that, having consulted with the Company's Nominated Adviser, the terms of their subscription are fair and reasonable insofar as the Company's shareholders are concerned.

Canadian Securities Law Matters

The Directors' Subscription will constitute a related party transaction pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the requirements to obtain a formal valuation and minority shareholder approval in connection with the Directors' Subscription in reliance on sections 5.5(a) and 5.7(a), respectively, of MI 61-101, as neither the fair market value of the securities received by such parties nor the proceeds for such securities received by the Company exceeds 25% of the Company's market capitalisation as calculated in accordance with MI 61-101. The board of directors of the Company has approved the Placing, with Jim Mellon abstaining from voting.

A material change report with respect to the Placing is expected to be filed less than 21 days prior to the closing of the Placing. This time period is reasonable and necessary in the circumstances as the Company wishes to complete the transaction on an expedited basis for sound business reasons.

Special note concerning the Market Abuse Regulation

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 ("MAR"). Market soundings, as defined in MAR, were taken in respect of the Placing, with the result that certain persons became aware of inside information, as permitted by MAR. That inside information is set out in this announcement. Therefore, those persons that received inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

For further information please visit www.condorgold.com or contact:

Condor Gold plc
Mark Child, Chairman and CEO
+44 (0) 20 7493 2784

Beaumont Cornish Limited
Roland Cornish and James Biddle
+44 (0) 20 7628 3396

SP Angel Corporate Finance LLP
Ewan Leggat
+44 (0) 20 3470 0470

Blytheweigh
Tim Blythe, Camilla Horsfall and Megan Ray
+44 (0) 20 7138 3204

About Condor Gold plc:

Condor Gold plc was admitted to AIM in May 2006 and dual listed on the TSX in January 2018. The Company is a gold exploration and development company with a focus on Nicaragua.

In August 2018, the Company announced that the Ministry of the Environment in Nicaragua had granted the Company an Environmental Permit for the development, construction and operation of a processing plant with capacity to process up to 2,800 tonnes per day at its wholly-owned La India gold project ("La India Project"). The Environmental Permit is considered to be the master permit for mining operations in Nicaragua. Condor Gold published a Pre-Feasibility Study ("PFS") on the La India Project in December 2014, as summarised in the Technical Report as defined below. The PFS details an open pit gold Mineral Reserve in the Probable category of 6.9 Mt at 3.0 g/t gold for 675,000 oz gold, producing 80,000 oz gold per annum for seven years. La India Project contains a Mineral Resource of 9,850Kt at 3.6 g/t gold for 1,140Koz gold in the Indicated category and 8,479Kt at 4.3g/t gold for 1,179Koz gold in the Inferred category. The Indicated Mineral Resource is inclusive of the Mineral Reserve.

Environmental Permits have also been granted in April and May 2020 in relation to the Mestiza and America open pits respectively, both located in the vicinity of the La India Project. The Mestiza open pit hosts 92Kt at a grade of 12.1 g/t gold (36,000 oz contained gold) in the Indicated Mineral Resource category and 341Kt at a grade of 7.7 g/t gold (85,000 oz contained gold) in the Inferred Mineral Resource category. The America open pit hosts 114 Kt at a grade of 8.1 g/t gold (30,000 oz contained gold) in the Indicated Mineral Resource category and 677Kt at a grade of 3.1 g/t gold (67,000 oz contained gold) in the Inferred Mineral Resource category. Following the permitting of the Mestiza and America open pits, together with the La India open pit Condor has 1.12M oz gold open pit Mineral Resources permitted for extraction, inclusive of a Mineral Reserve of 6.9Mt at 3.0g/t gold for 675,000 oz gold.

Disclaimer

Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

Qualified Persons

The technical and scientific information in this press release has been reviewed, verified and approved by Andrew Cheatle, P.Geo., who is a "qualified person" as defined by NI 43-101.

Technical Information

Certain disclosure contained in this news release of a scientific or technical nature has been summarised or extracted from the technical report entitled "Technical Report on the La India Gold Project, Nicaragua, December 2014", dated November 13, 2017 with an effective date of December 21, 2014 (the "Technical Report"), prepared in accordance with NI 43-101. The Technical Report was prepared by or under the supervision of Tim Lucks, Principal Consultant (Geology & Project Management), Gabor Bacsfalusi, Principal Consultant (Mining), Benjamin Parsons, Principal Consultant (Resource Geology), each of SRK Consulting (UK) Limited, and Neil Lincoln of Lycopodium Minerals Canada Ltd., each of whom is an independent "qualified person" as defined by NI 43-101.

Forward Looking Statements

All statements in this press release, other than statements of historical fact, are ‘forward-looking information' with respect to the Company within the meaning of applicable securities laws, including statements with respect to: the future development and production plans at La India Project. Forward-looking information is often, but not always, identified by the use of words such as: "seek", "anticipate", "plan", "continue", "strategies", "estimate", "expect", "project", "predict", "potential", "targeting", "intends", "believe", "potential", "could", "might", "will" and similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including, among others, assumptions regarding: future commodity prices and royalty regimes; availability of skilled labour; timing and amount of capital expenditures; future currency exchange and interest rates; the impact of increasing competition; general conditions in economic and financial markets; availability of drilling and related equipment; effects of regulation by governmental agencies; the receipt of required permits; royalty rates; future tax rates; future operating costs; availability of future sources of funding; ability to obtain financing and assumptions underlying estimates related to adjusted funds from operations. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct.

Such forward-looking information involves known and unknown risks, which may cause the actual results to be materially different from any future results expressed or implied by such forward-looking information, including, risks related to: mineral exploration, development and operating risks; estimation of mineralisation, resources and reserves; environmental, health and safety regulations of the resource industry; competitive conditions; operational risks; liquidity and financing risks; funding risk; exploration costs; uninsurable risks; conflicts of interest; risks of operating in Nicaragua; government policy changes; ownership risks; permitting and licencing risks; artisanal miners and community relations; difficulty in enforcement of judgments; market conditions; stress in the global economy; current global financial condition; exchange rate and currency risks; commodity prices; reliance on key personnel; dilution risk; payment of dividends; as well as those factors discussed under the heading "Risk Factors" in the Company's annual information form for the fiscal year ended December 31, 2019 dated March 31, 2020, available under the Company's SEDAR profile at www.sedar.com.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Jim Mellon

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jim Mellon

2

Reason for notification

a)

Position / status

Non-Executive Director

b)

Initial notification

/Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Condor Gold plc

b)

LEI

213800PFKETQA86RHL82

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

2,247,150 Ordinary shares of 20 pence each in Condor Gold plc

ISIN GB00B8225591

Nature of the transaction

Director's participation in a Subscription

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

36.5 pence

2,247,150

d)

Aggregated information

n/a

e)

Date of the transaction

29 May 2020

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

Andrew Cheatle

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Andrew Cheatle

2

Reason for notification

a)

Position / status

Non-Executive Director

b)

Initial notification

/Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Condor Gold plc

b)

LEI

213800PFKETQA86RHL82

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

10,000 Ordinary shares of 20 pence each in Condor Gold plc

ISIN GB00B8225591

Nature of the transaction

Director's participation in a Subscription

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

36.5 pence

10,000

d)

Aggregated information

n/a

e)

Date of the transaction

28 May 2020

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

Mark Child

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mark Child

2

Reason for notification

a)

Position / status

Executive Chairman

b)

Initial notification

/Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Condor Gold plc

b)

LEI

213800PFKETQA86RHL82

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

27,397 Ordinary shares of 20 pence each in Condor Gold plc

ISIN GB00B8225591

Nature of the transaction

Director's participation in a Subscription

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

36.5 pence

27,397

d)

Aggregated information

n/a

e)

Date of the transaction

28 May 2020

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

Jeffrey Karoly

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jeffrey Karoly

2

Reason for notification

a)

Position / status

Chief Financial Officer

b)

Initial notification

/Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Condor Gold plc

b)

LEI

213800PFKETQA86RHL82

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

10,000 Ordinary shares of 20 pence each in Condor Gold plc

ISIN GB00B8225591

Nature of the transaction

Participation in a Subscription

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

36.5 pence

10,000

d)

Aggregated information

n/a

e)

Date of the transaction

28 May 2020

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

Ian Stalker

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ian Stalker

2

Reason for notification

a)

Position / status

Non-Executive Director

b)

Initial notification

/Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Condor Gold plc

b)

LEI

213800PFKETQA86RHL82

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

67,370 Ordinary shares of 20 pence each in Condor Gold plc

ISIN GB00B8225591

Nature of the transaction

Participation in a Subscription

c)

Price(s) and volumes(s)

Price(s)

Volumes(s)

36.5 pence

67,370

d)

Aggregated information

n/a

e)

Date of the transaction

28 May 2020

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

SOURCE: Condor Gold plc

ReleaseID: 591728

LOS ANGELES, CA / ACCESSWIRE / May 28, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between January 10, 2020 and May 06, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before July 20, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Elanco consolidated its distributors from eight different organizations to four, and then increased the amount of inventory held by each distributor. These distributors did not demonstrate a sufficient level of demand to sell through the increased inventory, leading to both a decline in inventory and the Company reducing its channel inventory. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Elanco, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 591831